Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Birgit Geoerger

Showing results (121-130 of 179) with videos related to

Pageof 18
Sort By:
European Journal of Cancer (Oxford, England : 1990)|February 20, 2024
Clinical trial inclusion in patients with relapsed/refractory neuroblastoma following the European Precision Cancer Medicine trial MAPPYACTSJordane Chaix, Gudrun Schleiermacher, Nadège Corradini, et al.
Plos One|March 6, 2012
Mesenchymal transition and PDGFRA amplification/mutation are key distinct oncogenic events in pediatric diffuse intrinsic pontine gliomasStephanie Puget, Cathy Philippe, Dorine A Bax, et al.
EMBO Molecular Medicine|July 15, 2024
DiPRO1 distinctly reprograms muscle and mesenchymal cancer cellsJeremy Rich, Melanie Bennaroch, Laura Notel, et al.
Pediatric Blood & Cancer|October 10, 2019
Phase II study of temozolomide and topotecan (TOTEM) in children with relapsed or refractory extracranial and central nervous system tumors including medulloblastoma with post hoc Bayesian analysis: A European ITCC studyGwénaël Le Teuff, Alicia Castaneda-Heredia, Christelle Dufour, et al.
Pediatric Blood & Cancer|September 21, 2021
Comprehensive analysis of the ErbB receptor family in pediatric nervous system tumors and rhabdomyosarcomaPascale Varlet, Eric Bouffet, Michela Casanova, et al.
European Journal of Cancer (Oxford, England : 1990)|September 12, 2013
Phase II study of temozolomide in combination with topotecan (TOTEM) in relapsed or refractory neuroblastoma: a European Innovative Therapies for Children with Cancer-SIOP-European Neuroblastoma studyAngela Di Giannatale, Nathalie Dias-Gastellier, Annick Devos, et al.
European Journal of Cancer (Oxford, England : 1990)|July 17, 2024
Precision cancer medicine platform trials: Concepts and design of AcSé-ESMARTBirgit Geoerger, Francisco Bautista, Nicolas André, et al.
Cancers|October 23, 2020
SFCE-RAPIRI Phase I Study of Rapamycin Plus Irinotecan: A New Way to Target Intra-Tumor Hypoxia in Pediatric Refractory CancersSarah Jannier, Véronique Kemmel, Consuelo Sebastia Sancho, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 12, 2019
A Phase I and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients with Recurrent or Refractory <i>BRAF</i> V600 Mutation-Positive Solid TumorsMark W Kieran, Birgit Geoerger, Ira J Dunkel, et al.
Frontiers in Immunology|February 6, 2024
Divergent HLA variations and heterogeneous expression but recurrent HLA loss-of- heterozygosity and common <i>HLA-B</i> and <i>TAP</i> transcriptional silencing across advanced pediatric solid cancersWan Ching Lim, Maria Eugenia Marques Da Costa, Karine Godefroy, et al.
Pageof 18

Showing results (121-130 of 179) with videos related to

Sort By:
Pageof 18
European Journal of Cancer (Oxford, England : 1990)|February 20, 2024
Clinical trial inclusion in patients with relapsed/refractory neuroblastoma following the European Precision Cancer Medicine trial MAPPYACTSJordane Chaix, Gudrun Schleiermacher, Nadège Corradini, et al.
Plos One|March 6, 2012
Mesenchymal transition and PDGFRA amplification/mutation are key distinct oncogenic events in pediatric diffuse intrinsic pontine gliomasStephanie Puget, Cathy Philippe, Dorine A Bax, et al.
EMBO Molecular Medicine|July 15, 2024
DiPRO1 distinctly reprograms muscle and mesenchymal cancer cellsJeremy Rich, Melanie Bennaroch, Laura Notel, et al.
Pediatric Blood & Cancer|October 10, 2019
Phase II study of temozolomide and topotecan (TOTEM) in children with relapsed or refractory extracranial and central nervous system tumors including medulloblastoma with post hoc Bayesian analysis: A European ITCC studyGwénaël Le Teuff, Alicia Castaneda-Heredia, Christelle Dufour, et al.
Pediatric Blood & Cancer|September 21, 2021
Comprehensive analysis of the ErbB receptor family in pediatric nervous system tumors and rhabdomyosarcomaPascale Varlet, Eric Bouffet, Michela Casanova, et al.
European Journal of Cancer (Oxford, England : 1990)|September 12, 2013
Phase II study of temozolomide in combination with topotecan (TOTEM) in relapsed or refractory neuroblastoma: a European Innovative Therapies for Children with Cancer-SIOP-European Neuroblastoma studyAngela Di Giannatale, Nathalie Dias-Gastellier, Annick Devos, et al.
European Journal of Cancer (Oxford, England : 1990)|July 17, 2024
Precision cancer medicine platform trials: Concepts and design of AcSé-ESMARTBirgit Geoerger, Francisco Bautista, Nicolas André, et al.
Cancers|October 23, 2020
SFCE-RAPIRI Phase I Study of Rapamycin Plus Irinotecan: A New Way to Target Intra-Tumor Hypoxia in Pediatric Refractory CancersSarah Jannier, Véronique Kemmel, Consuelo Sebastia Sancho, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 12, 2019
A Phase I and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients with Recurrent or Refractory <i>BRAF</i> V600 Mutation-Positive Solid TumorsMark W Kieran, Birgit Geoerger, Ira J Dunkel, et al.
Frontiers in Immunology|February 6, 2024
Divergent HLA variations and heterogeneous expression but recurrent HLA loss-of- heterozygosity and common <i>HLA-B</i> and <i>TAP</i> transcriptional silencing across advanced pediatric solid cancersWan Ching Lim, Maria Eugenia Marques Da Costa, Karine Godefroy, et al.
Pageof 18